RecruitingNCT07341503
The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients
Sponsor
Ohio State University Comprehensive Cancer Center
Enrollment
100 participants
Start Date
Aug 18, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study is being done to learn more about breast cancer patients' experiences with sleep changes during cancer treatment, identify possible reasons for poor sleep quality, and to find out how stress, social support, and living environment affect sleep.
Eligibility
Min Age: 18 Years
Inclusion Criteria9
- \* Age \>= 18 years old at time of breast cancer diagnosis
- Stage I to III breast cancer diagnosis
- Hormone receptor positive breast cancers
- Post primary surgery, before chemotherapy/radiation therapy begins
- No known evidence of breast cancer recurrence (local or distant) or second, primary cancer
- No prior history of new other malignancy since their breast cancer diagnosis (other than non-melanoma skin cancer)
- Able to speak, understand and read English
- Cognitively able to complete the study requirements
- Ability to access medical records from treating hospital
Exclusion Criteria3
- \* Stage IV or metastatic breast cancer
- Not cognitively able to provide informed consent
- Not willing to provide informed consent
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07341503
Related Trials
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
NCT06418204467 locations
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT045504944 locations
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT0567320010 locations
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377475 locations
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT054227946 locations